ASLAN Pharmaceuticals Limited (ASLN)

ASLAN Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	12	12	0	0	0	3
Cost of Revenue	0	0	0	0	0	0.41
Gross Profit	12	12	0	0	0	2.59
Selling, General & Admin	12.59	13.24	9.88	11.83	7.17	8.51
Research & Development	34.33	42.5	38	22.02	9.31	16.59
Other Operating Expenses	0	0	0	0	0	23.07
Operating Expenses	46.92	55.74	47.88	33.85	16.48	48.17
Operating Income	-34.92	-43.74	-47.88	-33.85	-16.48	-45.58
Interest Expense / Income	3.92	4.33	3.68	1.86	1.25	0.9
Other Expense / Income	-3.95	-3.98	-0.27	-4.12	-0.76	0.18
Pretax Income	-34.9	-44.09	-51.28	-31.59	-16.97	-46.66
Income Tax	0.13	0.13	0.1	0	0	0.41
Net Income	-35.03	-44.22	-51.38	-31.59	-16.97	-47.07
Shares Outstanding (Basic)	467	411	349	326	192	162
Shares Outstanding (Diluted)	-	411	349	326	192	162
Shares Change	25.91%	17.93%	7.07%	69.43%	18.37%	8.45%
EPS (Basic)	-14.00	-22.00	-30.00	-20.00	-16.00	-58.00
EPS (Diluted)	-14.00	-22.00	-30.00	-20.00	-16.00	-58.00
Free Cash Flow	-	-43.33	-35.99	-34.04	-15.05	-25.51
Free Cash Flow Per Share	-	-21.07	-20.64	-20.91	-15.66	-31.41
Gross Margin	100.00%	100.00%	-	-	-	86.42%
Operating Margin	-291.03%	-364.46%	-	-	-	-1519.30%
Profit Margin	-291.89%	-368.50%	-	-	-	-1568.85%
Free Cash Flow Margin	-	-361.09%	-	-	-	-850.21%
EBITDA	-	-39.41	-47.28	-29.45	-15.43	-45.31
EBITDA Margin	-	-328.39%	-	-	-	-1510.35%
Depreciation & Amortization	-	0.35	0.33	0.28	0.3	0.45
EBIT	-30.98	-39.76	-47.61	-29.73	-15.72	-45.76
EBIT Margin	-258.15%	-331.29%	-	-	-	-1525.20%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).